Table A2.17Utility values used in the cost-effectiveness analysis

Health stateValueDistributionSource
Metastatic disease, stable0.51Beta (assumed se = 0.1)Best et al. 2010
Metastatic disease, progressive0.21Beta (assumed se = 0.1)Best et al. 2010
Disutility febrile neutropenia−0.15FixedLloyd et al. 2006
Disutility grade 3/4 diarrhoea−0.103FixedLloyd et al. 2006
Disutility grade 3/4 hand foot syndrome−0.116FixedLloyd et al. 2006

From: Appendix 2, Mixed treatment comparison and cost-effectiveness analysis for sequences of oxaliplatin and irinotecan-based chemotherapy in the treatment of advanced and metastatic colorectal cancer

Cover of Colorectal Cancer
Colorectal Cancer: The Diagnosis and Management of Colorectal Cancer.
NICE Clinical Guidelines, No. 131.
National Collaborating Centre for Cancer (UK).
Copyright © 2011, National Collaborating Centre for Cancer.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.